CXCR3 and neoplasm: Further studies to evaluate the different threshold levels of CXCL10 between tumor and immune cells to activate the CXCR3/pSrc pathway or to deliver tumor-selective CXCL10 inhibitors or CXCR3 inhibition will be considered.